Doxorubicin and Edelfosine Combo-Loaded Lipid–Polymer Hybrid Nanoparticles for Synergistic Anticancer Effect Against Drug-Resistant Osteosarcoma [Retraction]

Yang P, Zhang L, Wang T, et al. Onco Targets Ther. 2020;13:8055—8067. https://doi.org/10.2147/ott.s259428

We, the Editors and Publisher of the journal OncoTargets and Therapy, have retracted the published article.

After publication, concerns have been raised by a third party in 2026 about the integrity of the data in Figures 6 and 7 of the article.

Further investigation conducted by the Journal and Publisher confirmed unusual similarities present within the image panels representative of different treatment conditions in Figures 6, and 7.

When approached for an explanation, the authors did not respond to the queries raised by the Journal and Publisher.

As verifying the validity of published work is core to the integrity of the scholarly record, we are therefore retracting the article. The corresponding author listed in this publication has been informed.

We have been informed in our decision-making by our editorial policies and the COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as ‘Retracted’.